The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer
Dose reductions in CDK4/6 inhibitors were associated with worse survival outcomes in postmenopausal HR+ HER2- mBC patients. Future biomarker-driven studies are needed to guide personalized dose adjustments and optimize treatment efficacy.
Authors
- Öznur Bal (ORCID: https://orcid.org/0000-0002-6901-2646)
- Furkan Ceylan (ORCID: https://orcid.org/0000-0002-1944-0861)
- Burak Bi̇lgi̇n (ORCID: https://orcid.org/0000-0003-1717-8246)
- Safa Can Efil (ORCID: https://orcid.org/0000-0001-9586-2858)
- Eren Göktuğ Ceylan (ORCID: https://orcid.org/0009-0003-1244-4530)
- Mehmet Alı Nahıt Şendur (ORCID: https://orcid.org/0000-0001-7021-6139)
- Mutlu Hızal (ORCID: https://orcid.org/0000-0001-5147-4431)
- Şebnem Çınar Yücel (ORCID: https://orcid.org/0000-0002-8904-7395)
- Muhammed Bülent Akıncı (ORCID: https://orcid.org/0000-0001-7575-9925)
- Ateş Kutay Tenekeci (ORCID: https://orcid.org/0009-0007-6224-945X)
- Bülent Yalçın (ORCID: https://orcid.org/0000-0002-4431-8948)
- Didem Şener
Institutions
- University of Health Science (KH)
- Ankara Yıldırım Beyazıt University (TR)
- Hacettepe University (TR)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1080/14737140.2025.2490289
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52